ArticleJournal of chemical information and modeling2025
AstraMEV (AI-Guided Structural Assembly of Multi-Epitope Vaccines) Against Infectious Bronchitis Virus.
Article in Journal of chemical information and modeling, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
- Erratum issued
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Infectious bronchitis virus (IBV) continues to threaten the poultry industry due to its rapid mutation and genetic diversity. We introduce AstraMEV, a predictive structural immunoinformatic platform that leverages genomic screening of 56 IBV genomes to identify conserved epitopes from the nucleocapsid (N) and spike (S) proteins. Two multiepitope vaccine constructs, SmallTope and BigTope, were designed and refined using AI-driven methods such as RFdiffusion and ProteinMPNN to optimize structural stability and immunogenicity. Molecular dynamics simulations confirmed the constructs' stability and effective binding to chicken Toll-like receptor 4 (chTLR4). Crucially, Poisson-Boltzmann calculations revealed that certain computationally derived variant epitopes significantly improved the binding enthalpy, highlighting key interaction domains. Our comprehensive approach demonstrates the feasibility of leveraging computational immunoinformatics for targeted vaccine design. These findings underscore AstraMEV's robust potential for next-generation IBV vaccines and broader applications in combating rapidly evolving pathogens with significant global impact.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.